eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | chronic myelocytic leukemia |
| Comorbidity | C0023418|leukemia |
| Sentences | 13 |
| PubMedID- 26043219 | They are mainly found in acute myeloid leukemia and blastic phase of philadelphia chromosome-positive chronic myeloid leukemia, more rarely in myelodysplastic syndromes. |
| PubMedID- 22184394 | Hairy cell leukemia variant in a patient with chronic myeloid leukemia receiving nilotinib: sequential or coincidental. |
| PubMedID- 24152491 | Occurrence of chronic lymphocytic leukemia in patients with chronic myelogenous leukemia. |
| PubMedID- 21302443 | Objective: to study the proliferative inhibition effects of imatinib, daunorubicin and bortezomib on two leukemia cell lines with ph(+), chronic myelogenous leukemia cell line k562 expressing p210 protein and acute lymphoblastic leukemia cell line sup-b15 expressing p190 protein. |
| PubMedID- 20377918 | Introduction: the development of philadelphia chromosome (ph) negative acute leukemia/myelodysplastic syndrome (mds) in patients with ph-positive chronic myeloid leukemia (cml) is very rare. |
| PubMedID- 23192016 | Using a collection of 55 leukemia patients treated with tki therapy (chronic myeloid leukemia, n=47; acute lymphoblastic leukemia, n=8), we found that dasatinib, a second-generation broad-spectrum tki, induced a rapid, dose-dependent and substantial mobilization of non-leukemic lymphocytes and monocytes in blood peaking 1-2 h after an oral intake and the blood counts closely mirrored drug plasma concentration. |
| PubMedID- 21393960 | Exfoliative dermatitis with leukemia cutis in a patient with chronic myeloid leukemia: a rare association. |
| PubMedID- 26256879 | [development of ph negative acute myeloid leukemia in a patient with minor-bcr/abl positive chronic myeloid leukemia achieving a partial cytogenetic response during tyrosine kinase inhibitor treatment]. |
| PubMedID- 20922786 | Tyrosine kinase inhibitor (tki) treatment targeting breakpoint cluster region-abelson murine leukemia virus, the cause of chronic myeloid leukemia (cml), has revolutionized therapy for patients with this disease. |
| PubMedID- 24891015 | However, patients with bcr-abl1(+) acute lymphoblastic leukemia and subsets of patients with chronic myeloid leukemia are at high risk of relapse despite kinase inhibition therapy, necessitating novel treatment strategies. |
| PubMedID- 25745544 | Bone involvement can also rarely occur in acute lymphoblastic leukemia and blast crisis of chronic myeloid leukemia.12 other tumor presenting with predominant bone destruction at this age is ewing’s sarcoma. |
| PubMedID- 23738923 | Objective: molecular monitoring using quantitative polymerase chain reaction (qpcr) of bcr-abl mrna transcripts using the international scale (is) is recommended by the national comprehensive cancer network and the european leukemianet for patients with chronic myelogenous leukemia in chronic phase (cml-cp). |
| PubMedID- 22543830 | Philadelphia-negative acute promyelocytic leukemia in a patient with chronic myeloid leukemia in complete cytogenetic response after treatment with tyrosine kinase inhibitor. |
Page: 1